 | Up a level |
Sherman, Steven I; Wirth, Lori J; Droz, Jean-Pierre; Hofmann, Michael; Bastholt, Lars; Martins, Renato G; Licitra, Lisa; Eschenberg, Michael J; Sun, Yu-Nien; Juan, Todd; Stepan, Daniel E; Schlumberger, Martin J (2008). Motesanib diphosphate in progressive differentiated thyroid cancer. New England journal of medicine NEJM, 359(1), pp. 31-42. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa075853
Frilling, Andrea; Weber, Frank; Saner, Fuat; Bockisch, Andreas; Hofmann, Michael; Mueller-Brand, Jan; Broelsch, Christoph E (2006). Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery, 140(6), 968-76; discussion 976-7. New York, N.Y.: Elsevier 10.1016/j.surg.2006.07.030
Frilling, Andrea; Malago, Massimo; Weber, Frank; Paul, Andreas; Nadalin, Silvio; Sotiropoulos, Georgios C; Cicinnati, Vito; Beckebaum, Susanne; Bockisch, Andreas; Mueller-Brand, Jan; Hofmann, Michael; Schmid, Kurt W; Gerken, Guido; Broelsch, Christoph E (2006). Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver transplantation, 12(7), pp. 1089-96. Hoboken, N.J.: Wiley 10.1002/lt.20755
Geworski, L; Zöphel, K; Rimpler, A; Barth, I; Lassmann, M; Sandrock, D; Zander, A; Halm, T; Hänscheid, H; Hofmann, M; Reiners, Chr; Munz, D L (2006). [Radiation exposure in (90)Y-Zevalin therapy: results of a prospective multicentre trial]. Nuklearmedizin / Nuclear medicine, 45(2), 82-6; quiz N15-6. Stuttgart: Schattauer
